À propos de ce podcast
The clinical trial industry is stuck in an innovation impasse, weighed down by outdated processes, layers of bureaucracy, and a systemic inability to prioritize those on the frontlines - patients, sites, and researchers. Tune in every week as Tilda Research CEO Ram Yalamanchili interviews clinical trial leaders at the cutting edge of innovation who are breaking past the current paradigm.
Épisodes
- Gaurav Bhatnagar: The AI Reality Check · 19 minIn the final episode of Season 2 of Breaking Protocol, Ram Yalamanchili and Gaurav Bhatnagar reflect on the biggest lessons, themes, and insights from a season featuring clinical…
- George Magrath: AI-native Biotechs Have Arrived · 31 minGeorge Magrath, MD, CEO of Opus Genetics, joins Ram Yalamanchili to discuss how Opus is approaching portfolio-scale biotech development with multiple active clinical programs…
- Paulius Ojeras: AI is Changing the Clinical Trial Cost Equation · 41 min · Saison 2 Épisode 6AI is about to force a much bigger conversation in clinical research than most people realize. In this episode, Ram Yalamanchili, CEO of Tilda Research, and Paulius Ojeras, VP of…
- Shobhit Shrotriya: Pharma is Moving from AI Pilots to Production · 46 min · Saison 2 Épisode 6In this episode, Ram Yalamanchili sits down with Shobhit Shrotriya, Managing Director of Global Life Sciences R&D Operations at Accenture, to unpack what it will actually take…
- Ash Jayagopal: Closing the Clinical Research Innovation Gap · 31 min · Saison 2 Épisode 5Clinical trials have become more scientifically sophisticated, yet many of the operational challenges behind them remain stubbornly unchanged. In this episode of Breaking…
- Krishna Cheriath: AI is Disrupting Clinical Research Already · 42 min · Saison 2 Épisode 4Enterprise software has dominated how companies operate for decades. Krishna Cheriath, Head of Clinical Research Data and AI at Thermo Fischer Scientific, believes that model is…
- Alex Mok: Building Biotechs in the AI Era · 60 min · Saison 2 Épisode 3Drug development is both a science challenge and timeline challenge. In this episode, Alex Mok shares what it actually takes to build a biotech company in today’s market. From…
- Paula Brown Stafford: Modernizing Trials Without Breaking Them · 50 min · Saison 2 Épisode 2In this episode of Breaking Protocol, Ram Yalamanchili sits down with Paula Brown-Stafford, CEO of Allucent and one of the early architects of the CRO industry. From joining…
- Dr. Tom Mather: De-risking Drug Development with AI · 46 min · Saison 2 Épisode 1In this episode of Breaking Protocol, Tilda Research CEO Ram Yalamanchili sits down with Dr. Tom Mather — Chief Medical Officer of a clinical-stage biotech, early-stage venture…
- Dr. Mark Barakat: How AI reinvents clinical trials · 26 min · Saison 1 Épisode 5What happens when a retina specialist with a background in computer science takes on the inefficiencies of clinical research?In this insightful conversation, Dr. Mark Barakat of…
- Dr. Houman Hemmati: Clinical Trials Fail in the Execution: It doesn't have to be this way · 46 min · Saison 1 Épisode 4In a recent conversation, Dr. Houman Hemmati (ophthalmologist, clinical trialist, and biotech innovator) didn’t hold back in describing the systemic inefficiencies he sees every…
- Dr. James Fox: Scaling Clinical Research with AI Teammates · 56 min · Saison 1 Épisode 3ICON Eyecare experiences 66% data quality improvement and 90% increase in efficiency. Dr. James Fox of ICON Eyecare (Grand Junction, CO) discusses what it really takes to scale…
- Dr. David Chin Yee: Streamlining Clinical Trials · 35 min · Saison 1 Épisode 2Transforming Clinical Trials with AI: An in-depth Discussion with Dr. David Chin YeeDr. David Chin Yee, Research Director at Georgia Retina shares his journey and the…
- Dr. George Magrath: How Opus Breaks Trial Bottlenecks · 48 min · Saison 1 Épisode 1A powerful conversation with Dr. George Magrath, CEO of Opus Genetics and seasoned ophthalmologist, as he shares how AI is reshaping clinical trials, and the incredible impact of…
